Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) hit a new 52-week high during trading on Thursday following a stronger than expected earnings report. The stock traded as high as $25.07 and last traded at $23.98, with a volume of 64946 shares trading hands. The stock had previously closed at $20.45.
The biopharmaceutical company reported $0.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.18. The firm had revenue of $49.13 million during the quarter, compared to analyst estimates of $49.44 million. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. Vanda Pharmaceuticals’s revenue was up 18.9% on a year-over-year basis. During the same period last year, the firm posted ($0.03) EPS.
VNDA has been the subject of several research analyst reports. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $23.00 price objective for the company in a research report on Sunday, July 15th. Cantor Fitzgerald initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, August 22nd. They issued a “neutral” rating and a $26.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, September 13th. They issued a “buy” rating and a $30.00 price objective for the company. Citigroup increased their price objective on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, October 16th. Finally, Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, September 20th. They issued a “buy” rating and a $29.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $27.43.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its holdings in shares of Vanda Pharmaceuticals by 665.9% in the 1st quarter. Russell Investments Group Ltd. now owns 44,065 shares of the biopharmaceutical company’s stock valued at $742,000 after acquiring an additional 38,312 shares in the last quarter. UBS Group AG grew its holdings in Vanda Pharmaceuticals by 35.9% during the first quarter. UBS Group AG now owns 84,739 shares of the biopharmaceutical company’s stock worth $1,428,000 after purchasing an additional 22,382 shares during the period. Allianz Asset Management GmbH grew its holdings in Vanda Pharmaceuticals by 2.9% during the first quarter. Allianz Asset Management GmbH now owns 136,218 shares of the biopharmaceutical company’s stock worth $2,295,000 after purchasing an additional 3,903 shares during the period. Xact Kapitalforvaltning AB bought a new position in Vanda Pharmaceuticals during the second quarter worth about $240,000. Finally, Fox Run Management L.L.C. grew its holdings in Vanda Pharmaceuticals by 23.9% during the second quarter. Fox Run Management L.L.C. now owns 28,611 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 5,516 shares during the period. 93.92% of the stock is owned by institutional investors.
The firm has a market capitalization of $1.05 billion, a P/E ratio of -68.03 and a beta of 1.06.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Macon Daily and is owned by of Macon Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://macondaily.com/2018/11/10/vanda-pharmaceuticals-vnda-sets-new-12-month-high-following-earnings-beat.html.
About Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: What is Liquidity?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.